Genomic Heterogeneity of Pancreatic Ductal Adenocarcinoma and Its Clinical Impact

SIMPLE SUMMARY: Although much progress has been made in recent years in the clinical management of solid tumors, pancreatic ductal adenocarcinoma (PDAC) remains a malignancy with limited therapeutical options. Indeed, responses to standard chemotherapy and targeted therapies vary widely when adminis...

Descripción completa

Detalles Bibliográficos
Autores principales: Gutiérrez, María Laura, Muñoz-Bellvís, Luis, Orfao, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430663/
https://www.ncbi.nlm.nih.gov/pubmed/34503261
http://dx.doi.org/10.3390/cancers13174451

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430663/
https://www.ncbi.nlm.nih.gov/pubmed/34503261
http://dx.doi.org/10.3390/cancers13174451

Ejemplares similares